Business Wire

DATAGUARD

5.6.2024 17:29:34 CEST | Business Wire | Press release

Share
DataGuard Acquires DPOrganizer to Accelerate International Expansion

DataGuard, a leading Software-as-a-Service (SaaS) company for security and compliance, announced today that it has acquired DPOrganizer. This acquisition expands DataGuard’s footprint particularly in the Nordic region and the UK, and strengthens the company’s market position across its core geographies Europe and North America. DataGuard helps over 4,000 customers active in more than 50 countries build robust security and compliance management systems. Companies use DataGuard’s software platform to get certified and become compliant with frameworks (such as GDPR, CCPA, ISO 27001, NIS 2, or SOC 2) as well as manage their most important risks efficiently, thereby staying ahead of evolving business and regulatory needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605633259/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Security & Compliance Management Software (Photo: Business Wire)

DPOrganizer, a Stockholm-based privacy management solution for privacy professionals and in-house data protection and compliance teams, helps small and large customers in more than 20 countries build and run effective privacy programs, comply with regulation, and build trust with their customers and partners. DPOrganizer’s powerful software toolkit offers incidents and breach management, data subject request handling, data protection impact assessments, and more functionalities. Thanks to the advanced data mapping, analytics and data flow visualization capabilities, data protection officers and privacy professionals can ensure collection and retention of data in line with regulation and best practice, identifying patterns and anomalies, and preventing breaches or non-compliance.

"Today’s announcement is a major milestone on DataGuard’s growth journey. Integrating DPOrganizer’s capabilities will enhance our offering for customers. It helps us build a unique system-of-record for the security and compliance domain that lets companies go beyond certifications and tick-the-box exercises,” says Thomas Regier, co-founder and co-CEO at DataGuard. “This and our comprehensive risk-first approach give DataGuard an asymmetric advantage as we transition into the era of AI-piloted security and compliance programs. We will continue to integrate strategic tech partners natively into our software ecosystem – to further broaden our customer value proposition and expand our geographic footprint.”

“In the era of data and artificial intelligence, organisations are constantly exposed to an increasing number of cyber threats and are required to comply with a multitude of frameworks to continue their business operations. As we know from our customers, ‘the risk is real’, and we believe the best way to address this is to have an effective digital information security and compliance management system. Partnering with DPOrganizer helps us further this mission,” said Kivanc Semen, co-founder and co-CEO at DataGuard.

“DPOrganizer was built for and is loved by privacy and compliance professionals. By joining forces with DataGuard, we can add capabilities such as the AI copilot, asset management, risk and controls management, and numerous information security frameworks. We thereby enable customers to build the bridge between security and compliance, expert and non-expert, business and compliance people. I am beyond excited to start this joint journey and combine our deep domain expertise and technological capabilities. We will continue to give thousands of customers a best-in-class experience,” Egil Bergenlind, co-founder of DPOrganizer summarizes.

About DataGuard

DataGuard is a security and compliance software company trusted by more than 4,000 organisations across the globe. Customers use the platform to build up a scalable risk management and a strong security posture while getting certified fast and complying effortlessly with industry regulation and frameworks such as ISO 27001, TISAX®, NIS2, SOC2, GDPR, and the EU Whistleblower Directive. Our purpose-built software suite offers AI-powered workflow automation and seamless integration capabilities, reducing the time and money organisations spend to build a digital Information Security Management System (ISMS) and Compliance Management System (CMS). DataGuard empowers organisations active in 50+ countries to better understand, identify, and manage the risks that matter most to them – and to build up a robust security and compliance posture that allows them to stay ahead of their evolving business and regulatory needs.

www.dataguard.com

About DPOrganizer

DPOrganizer is a market leading provider of privacy management software that helps privacy professionals in 20+ countries to build more effective and sustainable data protection programs. The company offers an intuitive and easy to use software supporting customers with data mapping, assessment automation, reporting and visualization, data protection trainings, data subject request and incident management.

www.dporganizer.com

TISAX® is a registered trademark of the ENX Association. DataGuard is not affiliated with the ENX Association.

We provide Software-as-a-Service and support for the assessment on TISAX® only.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605633259/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye